Synergistic Cytotoxicity of the Multikinase Inhibitor Sorafenib with the DNA Alkylating Agent Busulfan, and Nucleoside Analogs in Human FLT3-ITD-Positive Acute Myeloid Leukemia Cell Lines

Abstract

s / Biol Blood Marrow Transplant 20 (2014) S151eS164 S158 AML (rAML) is poor ( 180 days, incidence of GVHD, relapse rate and one year progression-free (PFS) and OS. Results: Patients: Five patients have been enrolled. One patient had rAML following two induction attempts. Another patient had rAML (secondary) after one induction attempt and three had relapsed ( 50% blast cells in the marrow. Toxicity: day 100, involving the GI tract (n1⁄42) and liver (n1⁄42). One patient has persistent cGVHD beyond 4 months involving the mouth and lungs. Response: Of the 4 patients who had circulating blast cells, all were cleared by day 1. Two patients are in continuous CR on days 217 and 338. Three patients have relapsed at days 96, 110 and 139 and died on days 106, 145 and 257, respectively. Conclusion: rAML is controlled by ED-TBI followed by an alloHCT. The toxicity of ED-TBI is acceptable and comparable to other alloHCT conditioning regimens. Safety and efficacy are continuing to be assessed with a goal to recruit 20 patients.